ArticleMolecules (Basel, Switzerland)2026
RBM5 Acts as a Tumor Suppressor in Breast Cancer Through Binding to G-quadruplexes in the BAP1 Gene Promoter to Activate Its Expression.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
As a member of the RNA-binding motif protein (RBM) family, RBM5 is a characterized tumor suppressor in lung and prostate cancers, with critical roles in alternative splicing of apoptosis- and cell cycle-related genes. However, its direct capacity to regulate gene transcription remains unreported. Here, we identified that RBM5 was significantly downregulated in breast cancer cells and clinical specimens, especially in the basal-like subtype. RBM5 overexpression attenuated breast cancer cell malignancy, while RBM5 knockdown exerted opposite effects. Among genes with promoter G-quadruplex (G4) motifs, RBM5 was positively correlated with multiple tumor suppressors, including BAP1, but uncorrelated with the oncogene MYC. RBM5 bound to G4 motifs in both MYC and BAP1 promoters, but differentially modulated G4 structure stability: it destabilized MYC-G4 while stabilizing BAP1-G4. Mechanistically, either the RRM1 or the RRM2 domain was sufficient for MYC-G4 binding, whereas both domains were required for BAP1-G4 interaction. RBM5 manipulation regulated endogenous BAP1 but not MYC expression. BAP1 overexpression reversed the protumorigenic effects of RBM5 knockdown in cellulo and tumor growth in a xenograft mouse model. Collectively, we reveal that RBM5 acts as a breast cancer tumor suppressor via directly binding the BAP1 promoter G4 to transcriptionally activate BAP1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.